Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ASCO GU 2018: PROs and HRQoL of LATITUDE

Dr. Kim Chi, medical oncologist at the BC Cancer Agency in Vancouver, summarizes the results of the LATITUDE trial and the recently published patient-reported outcomes and health-related quality of life.

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congresnieuws 18/02/2017

​ASCO GU 2017: RT versus surgery in Gleason 9-10 Pca

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Amar Kishan Poster: A7 - Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era

Congresnieuws 12/03/2015

Oncology News Program at Genitourinary Cancers Symposium 2015

The 2015 Genitourinary Cancers Symposium was held in Orlando from February 26th to 28th. In a multidisciplinary Oncology News Program Dutch and Belgian experts will discuss new important data, presented at this congress. In the first part of this Oncology News Program Dr. Thierry Gil, Prof. Jeroen van Moorselaar and Dr. Fons van den Bergh talk about the role of Androgen Deprivation Therapy in early and intermediate risk prostate cancer, dose escalation in Radiotherapy, Stereotactic Body Radiotherapy and possible predictive markers like Slco2B1 and androgen receptor splice variant 7. The second part covers the following topics on prostate cancer: Active Surveillance in early stage prostate cancer, Brachytherapy versus External Beam Radiation Therapy, active immunotherapy and check point inhibitors and one of the highlights of this congress, the GETUG-15 trial. These data are discussed by Prof. Winald Gerritsen, Prof. Gert De Meerleer and Prof. Thierry Roumeguère. The panel for the last part of this Oncology News Program consists of Prof. Gerritsen, Prof. van Moorselaar and Prof. Roumeguère. The experts discuss important new data on GU-non prostate cancer: organ sparing versus radical cystectomy, (neo)adjuvant chemotherapy in bladder cancer, the role of profiling urothelial cancer, anti-PDL1 and Pazopanib in combination with Paclitaxel in refractory urothelial cancer. Presented by dr. Ayan Panja.

Congresnieuws 18/02/2017

ASCO GU 2017: Discussion program on prostate and bladder cancer

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. An international multidisciplinary panel discussed a selection of topics and new data on prostate and bladder cancer. During a live connection, questions were submitted by participants of the ASCO Direct GU Virtual meetings in 7 different countries (Austria, Belgium, Brazil, Germany, Netherlands, United Arabic Emirates and Switzerland) Topics: Active surveillance in localized prostate cancer Impact of ProtecT trial results Value of imaging, genomics, and genetics for active surveillance High-risk prostate cancer, definition and therapeutic controversies Value of chemoradiation for bladder cancer Molecular predictors and response to neoadjuvant chemotherapy in bladder cancer Speakers: Prof. Bertrand Tombal MD PhD, urologist, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium Prof. Robert Bristow MD PhD, radiation oncologist, Princess Margaret Hospital, Toronto, Canada Prof. Thomas Bauernhofer MD, medical oncologist, University Clinic for Internal Medicine Karl-Franzens University, Graz, Austria Neil Shore MD, urologist, Atlantic Urology Clinic, Myrtle Beach, USA Moderator: Catherine Hood PhD  

Congresnieuws 18/02/2017

ASCO GU 2017: Genomics of radioresistant Pca

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Melvin Chua Poster: A26 - Genomic architecture of radioresistant prostate cancer

Congresnieuws 09/01/2016

2016 GU Cancers Symposium News Program

Prof. Anthony D´Amico (Dana Faber & Harvard Cancer Institute, USA) and Prof. Nick James (Warwick Medical School, UK) discuss the highlights of the 2016 Genitourinary Cancers Symposium which took place in San Francisco from the 7th – 9th January 2016. Topics include a.o.: standard versus hypofractionated radiotherapy in prostate cancer (abstract 1 & 2) Anti Androgen Therapy after radical prostatectomy (abstract 3) update of the STAMPEDE trial (celecoxinib and zoledronic acida arms) (abstract 162) the role of circulating cell free DNA in profiling urothelial carcinoma (abstract 163) adjuvant radiation vs. chemo-radiation vs. chemotherapy alone after radical cystectomy for locally advanced bladder cancer (abstract 356)

Congresnieuws 18/02/2017

​ASCO GU 2017: RECARDO trial

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Esther Bouman-Wammes Poster: A166 - A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.

Congresnieuws 12/03/2015

GU Cancers Symposium 2015 Brussels

From February 26th to 28th the 2015 Genitourinary Cancers Symposium was held in Orlando. In a broadcasting from Orlando to Brussels Dr. Thierry Gil (Institut Jules Bordet), Prof. Gert De Meerleer (University Ghent) and Prof. Steven Joniau (UZ Leuven) interviewed Prof. Nick James (University of Warwick), Associate Prof. Paul Nguyen (Dana-Farber/Harvard Cancer Center) and Assistant Prof. Brian Chapin (MDAnderson Cancer Center). Topics: GETUG-15, CHAARTED, STAMPEDE trial. Both ph Combination of anti-PD(L)1 with other drugs Benefit of brachytherapy boost in comparison to external beam radiation Role of prostatectomy in high risk disease Treatment of primary tumors in metastatic prostate cancer